Life Science Partner recruits global leader in preclinical development to help accelerate product creation and add pharmaceutical expertise
Life Science Partner announces the recruitment of Andrew Penman, PhD, formerly president, preclinical development at Aptuit (a spin-out of Quintiles Transnational) to lead Angiotech Pharmaceuticals newly formed division of preclinical development. Angiotech is the world leader in the emerging field of drug-eluting medical devices and biomaterials. With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Penman will lead the preclinical development team to capitalize upon Angiotech’s considerable intellectual property portfolio to create breakthrough products.
A well-respected manager of preclinical development, Penman was responsible for a global team of 350 people worldwide and service revenues of $55m generated through contract preclinical services in the Kansas City and UK locations. The Company was formed by the spin-out of the preclinical group of Quintiles, a company in which he led the DMPK and Bioanalysis group.
“Andy is an excellent manager and preclinical scientist,” noted Cindi Roberts, vice president of Life Science Partner. “His experience in the contract-services business of preclinical drug development has honed his business and organizational skills.”
Penman joined Quintiles upon the acquisition of Pharmacia by Pfizer. Within the pharmaceutical industry, he was director, drug metabolism and biodisposition at the Pfizer Skokie site. He honed his skills in early drug development as President of Cephac Europe, a 100-scientist bioanalytic division of Aster-Cephac. His recruitment to Quintiles in 2003 was a return to the company he joined in 1995 in its Scotland-based bioanalysis group.
Penman earned his B.Sc. in Chemistry at Heriot-Watt University in Edinburgh and his Ph.D. at University of Kent in Canterbury.